Antirheumatic Therapy: Actions and Outcomes

  • Richard O. Day
  • Daniel E. Fürst
  • Piet L. C. M. van Riel
  • Barry Bresnihan

Part of the Progress in Inflammation Research book series (PIR)

Table of contents

  1. Front Matter
    Pages i-xiii
  2. Maria E. Suarez-Almazor
    Pages 25-47
  3. Andreas Maetzel, Daniel H. Solomon
    Pages 49-67
  4. Keystone Edward C., Haraoui Boulos
    Pages 69-80
  5. Bothwell Beau, Daniel E. Furst
    Pages 81-92
  6. Cees J. Haagsma
    Pages 93-132
  7. Rolf Rau
    Pages 133-161
  8. David Kanel, Barry Bresnihan
    Pages 163-173
  9. Kevin Pile
    Pages 175-197
  10. Alberta Hoi, Geoffrey Littlejohn
    Pages 199-219
  11. Arno W. R. van Kuijk, Ben A. C. Dijkmans
    Pages 221-236
  12. Kristin Bird, James R. O’Dell
    Pages 237-245
  13. John R. Kirwan, Mark G. Perry
    Pages 247-264
  14. Zuhre Tutuncu, Arthur Kavanaugh
    Pages 265-278
  15. Barry Bresnihan
    Pages 279-291
  16. Ernest Choy, Harold E. Paulus
    Pages 293-318
  17. Back Matter
    Pages 337-346

About this book


Our goal for this book is to examine the contemporary therapy of rheumatoid arthritis (RA) from the increasingly important perspective of impact upon quality of life, costs and long-term health outcomes. For too long the focus has been on short­ term, symptomatic, and surrogate indicator outcomes. Yet RA is a life-long disor­ der with the majority of impact on an individual patient many years following onset. Further, even in the short-term, researchers and rheumatologists have tended to emphasize measurements of disease activity such as joint counts, ESR and physi­ cian's opinion as to the amount of disease activity present. It is only relatively recently that measures of structural damage, quality of life and impact on broad domains of health have been given increasing emphasis. Also, the significance of early treatment of RA in order to optimise long-term outcomes has a relatively short history [1]. We have been focussed on the disease processes as surrogates for long­ term outcomes. Until the short-term process measures are validated as surrogates of long-term effects we should also turn our attention to outcomes of disease and the impact of our management on those outcomes [2). Inour view, this book is especially timely. We are at the dawn of a revolution in the management of RA and other complex immunological inflammatory disorders because their molecular, genetic and environmental mechanisms are being unrav­ elled. Inthe process, we are revealing a substantial number of novel and significant targets for pharmacotherapy.


Arthritis autoimmune disease cell chemistry diseases economics medicinal chemistry pharmacology quality of life research rheumatism rheumatoid arthritis therapy toxicity transplantation

Editors and affiliations

  • Richard O. Day
    • 1
  • Daniel E. Fürst
    • 3
  • Piet L. C. M. van Riel
    • 2
  • Barry Bresnihan
    • 4
  1. 1.Department of Clinical Pharmacology and ToxicologySt. Vincent’s Hospital SydneySydneyAustralia
  2. 2.546 Dept. of RheumatologyUniversity Hospital NijmegenNijmegenThe Netherlands
  3. 3.Carl M.Pearson Professor of RheumatologyLos AngelesUSA
  4. 4.Department of RheumatologySt Vicent’s University HospitalDublin 4Ireland

Bibliographic information